131 related articles for article (PubMed ID: 15623612)
1. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Thomas GV; Horvath S; Smith BL; Crosby K; Lebel LA; Schrage M; Said J; De Kernion J; Reiter RE; Sawyers CL
Clin Cancer Res; 2004 Dec; 10(24):8351-6. PubMed ID: 15623612
[TBL] [Abstract][Full Text] [Related]
2. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Wu X; Senechal K; Neshat MS; Whang YE; Sawyers CL
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15587-91. PubMed ID: 9861013
[TBL] [Abstract][Full Text] [Related]
3. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.
Asano T; Yao Y; Zhu J; Li D; Abbruzzese JL; Reddy SA
Oncogene; 2004 Nov; 23(53):8571-80. PubMed ID: 15467756
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Choe G; Horvath S; Cloughesy TF; Crosby K; Seligson D; Palotie A; Inge L; Smith BL; Sawyers CL; Mischel PS
Cancer Res; 2003 Jun; 63(11):2742-6. PubMed ID: 12782577
[TBL] [Abstract][Full Text] [Related]
5. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
6. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.
Manning BD; Tee AR; Logsdon MN; Blenis J; Cantley LC
Mol Cell; 2002 Jul; 10(1):151-62. PubMed ID: 12150915
[TBL] [Abstract][Full Text] [Related]
7. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
Newton HB
Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
[TBL] [Abstract][Full Text] [Related]
8. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B.
Lizcano JM; Alrubaie S; Kieloch A; Deak M; Leevers SJ; Alessi DR
Biochem J; 2003 Sep; 374(Pt 2):297-306. PubMed ID: 12841848
[TBL] [Abstract][Full Text] [Related]
9. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
10. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
11. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Van de Sande T; De Schrijver E; Heyns W; Verhoeven G; Swinnen JV
Cancer Res; 2002 Feb; 62(3):642-6. PubMed ID: 11830512
[TBL] [Abstract][Full Text] [Related]
12. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
13. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase.
Leenders F; Möpert K; Schmiedeknecht A; Santel A; Czauderna F; Aleku M; Penschuck S; Dames S; Sternberger M; Röhl T; Wellmann A; Arnold W; Giese K; Kaufmann J; Klippel A
EMBO J; 2004 Aug; 23(16):3303-13. PubMed ID: 15282551
[TBL] [Abstract][Full Text] [Related]
14. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling.
Radimerski T; Montagne J; Hemmings-Mieszczak M; Thomas G
Genes Dev; 2002 Oct; 16(20):2627-32. PubMed ID: 12381661
[TBL] [Abstract][Full Text] [Related]
15. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
16. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
17. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
18. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
19. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
20. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells.
Neri LM; Borgatti P; Tazzari PL; Bortul R; Cappellini A; Tabellini G; Bellacosa A; Capitani S; Martelli AM
Mol Cancer Res; 2003 Jan; 1(3):234-46. PubMed ID: 12556562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
